Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

eSupport and eFIT: Internet-based targeted behavioral interventions for persons with multiple sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (5:30 PM-6:30 PM)
9-009

To develop targeted telehealth interventions for persons with MS (pwMS): eSupport, online support groups to reduce loneliness and depression; eFIT, online accountability partner groups to increase physical activity. Both interventions leverage social ties to encourage and sustain healthy behavioral change.

Social network science reveals pwMS with stronger networks better maintain participation in cognitively-enhancing activities (physical and social leisure activities) compared to patients with weak networks. Many pwMS describe a sense of isolation and want to connect to other individuals who understand what they are going through. Online support groups and group-based targeted behavioral interventions address needs for social connection.

Feasibility trials of eSupport (NCT03574691; N=28) and eFIT (NCT038929267; N=17, actively recruiting) were conducted. Diversity of participants was notable: 69% female; 19.5% Hispanic, 16.5% Black, 2.4% Asian. Participants received 12-weeks of 1-hour weekly treatment or eJournal, active control condition. eSupport consisted of video-link, facilitated group meetings. eJournal consisted of independent online structured journaling.

Both trials demonstrated acceptable rates of adherence (eSupport: 88.9%; eFIT: 80.5%) and completion (eSupport: 96.4%; eFIT: 70.6%). Both treatments resulted in trend-level improvements in pre-specified efficacy outcomes [(eSupport: reduced loneliness based on UCLA Loneliness Scale, reduced depression based on Patient Health Questionnaire-9; eFIT: increased self-reported physical activity based on International Physical Activity Questionnaire (IPAQ)].

eSupport and eFIT are affordable, accessible, acceptable, and scalable telehealth treatments that leverage social network science to address clinically meaningful needs of pwMS. One participant stated, “This group is just about the best thing I’ve got going in my life right now.” Results of these feasibility trials constitute a necessary level of evidence to warrant future Phase-III trials.

Authors/Disclosures
Victoria Leavitt, PhD, FÂé¶¹´«Ã½Ó³»­ (Columbia University Irving Medical Center)
PRESENTER
Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Leavitt has received research support from National Institutes of Health. The institution of Dr. Leavitt has received research support from National Multiple Sclerosis Society. The institution of Dr. Leavitt has received research support from Department of Defense. Dr. Leavitt has received intellectual property interests from a discovery or technology relating to health care.
Philip De Jager, MD, PhD (Columbia University Irving Medical Center) Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from puretech.
Philip De Jager, MD, PhD (Columbia University Irving Medical Center) Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from puretech.
No disclosure on file